Durect reaches enrollment milestone in phase 2b ahfirm trial

Ahfirm enrollment surpasses 200 of the planned 300 ah patients enrollment completion now anticipated in q2 2023 cupertino, calif. , oct. 6, 2022 /prnewswire/ -- durect corporation (nasdaq: drrx), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ injury and chronic liver diseases, today announced the enrollment of more than 200 of the planned 300 patients in its phase 2b ahfirm trial.
DRRX Ratings Summary
DRRX Quant Ranking